Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28676966 | 0.84 | HDAC6 (0.54) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL2754167 | 0.83 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL11617583 | 0.82 | MEN1 (0.67) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL2640927 | 0.80 | MEN1 (0.69) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL966694 | 0.80 | MEN1 (0.69) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL7653262 | 0.80 | ALDH1A1 (0.66) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL1382123 | 0.80 | MEN1 (0.55) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL4294745 | 0.79 | MEN1 (0.67) | MEN1KMT2AALDH1A1TSHRGLA | |
| SCHEMBL965733 | 0.79 | MEN1 (0.67) | MEN1KMT2AALDH1A1TSHRGLA | |
| Hydrochloric Acid SCHEMBL27718102 | 0.79 | ALDH1A1 (0.63) | MEN1KMT2AALDH1A1TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651758-B | Synthetic method of benzo-hydrogenated imidazolone framework | 南通大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-113651758-A | Synthetic method of benzo-hydrogenated imidazolone framework | 南通大学 | 2021-11-16 | — | — | CN | disclosed |
| US-8207210-B2 | Aminoindazolylurea derivatives | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253767-A1 | AMINOINDAZOLYLUREA DERIVATIVES | SGK2, SGK1, SGK3 | MEN1 4191/4885KMT2A 2034/4885ALDH1A1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.